Skip to main content
. 2020 Sep 28;50(6):1262–1268. doi: 10.1016/j.semarthrit.2020.09.008

Fig. 2.

Fig. 2

Opinions of the pediatric rheumatologists regarding the management of patients using biologic disease modifying anti-rheumatic drugs (DMARDs) and initiating biologic DMARDs. COVID-19, coronavirus disease 2019.